Get started

Bioscience

Growing Revenue, TWST Set to Launch?Digital Health & Medical AI is on the rise ...and so is TWST's Revenue. It is tipped that artificial intelligence will play a key role in the development of industry wide efficiencies, with many advancements occurring over the last 12 months within the Medical Technologies space. One key player could be TWIST Bioscience Corporation NASDAQ:TWST , who have developed a synthetic DNA manufacturing process. Momentum Guide - Rating has now been upgraded to 'Bullish'. Here's our price guide: Bullish Continuation Potential above $48.71 Bearish Continuation Risk below $39.93 We're inspired to bring you the latest developments across worldwide markets, helping you look in the right place, at the right time - We will continue to monitor the Digital Health space in the event there are any rapid changes. Thank you for reading! Stay tuned for further updates, and we look forward to being of service along your trading & investing journey... Please note all information contained within this post is strictly for informational purposes only and is not intended to be investment advice. Please DYOR & Consult your licensed financial advisors before acting on any information contained within this post. Love & Wisdom,
NASDAQ:TWSTLong
by Bullfinder-official
"NBIX Stock Breaks All-Time Highs, Strong Buy Opportunity!"NBIX Stock Breaks All-Time Highs: A Strong Buy Opportunity Emerges Neurocrine Biosciences Inc. (NBIX) is currently making waves in the stock market as it breaks out of its all-time highs, signaling a promising opportunity for investors. After 14 years of steady upward momentum and price consolidation, NBIX appears poised for further growth, with technical indicators suggesting a bullish trend ahead. The recent surge in NBIX's stock price comes on the heels of strong performance and positive sentiment surrounding the company's products and pipeline. With a focus on innovative treatments for neurological and endocrine disorders, Neurocrine Biosciences has established itself as a leader in the biopharmaceutical industry, attracting investors seeking exposure to high-growth sectors. Technical analysis reveals that NBIX's current breakout is accompanied by the formation of a bull flag pattern, a bullish continuation pattern that often precedes further upward movement. This consolidation phase following a prolonged uptrend suggests that NBIX may be gearing up for another leg higher, providing an attractive entry point for investors. To capitalize on this potential opportunity, traders are advised to monitor the 4-hour time frame closely, watching for confirmation of the breakout and additional upside momentum. A sustained move above the current resistance levels could signal further strength in NBIX's stock price, potentially leading to a retest of its previous all-time highs. Investors considering a position in NBIX should also keep an eye on key support levels and market dynamics, as volatility in the broader market could impact the stock's trajectory. However, with a strong track record of growth and a robust pipeline of innovative therapies, NBIX appears well-positioned to weather any short-term fluctuations and deliver long-term value to shareholders. In conclusion, Neurocrine Biosciences Inc. is breaking out of its all-time highs, presenting a compelling buying opportunity for investors. With 14 years of upward momentum behind it and a bullish pattern forming, NBIX looks poised for further growth in the coming weeks and months. By monitoring the 4-hour time frame and remaining vigilant for additional breakouts, investors can position themselves to capitalize on the potential upside in NBIX's stock price.
NASDAQ:NBIXLong
by UnknownUnicorn2319099
Harvard Bioscience: Bouncing Higher From Multiple-Year SupportI zoomed all the way out to the monthly chart to show the long-term support levels. We can see that HBIO is bouncing higher from a multi-year support level in the $2 range. The MACD (middle of the chart) didn't confirm an upward trend yet. However, the MACD did confirm the upward trend on the weekly chart. It looks like the blue monthly MACD line is close to crossing above the red signal line. The purple RSI line on the bottom of the chart is pointing upward, which is bullish. This indicates that we could see a long-term continuation of the rally which began in December/January. Click on the link below for a detailed article. HBIO has a low valuation with strong expected EPS growth. This is likely to drive the stock higher IMO.
NASDAQ:HBIOLong
by Zman1175
Liminal BioSciences, a risky play85% below the July peak of last year and 99% below its all-time high. Orbiting a major support level around $4. A capital injection began in mid-November that is still not properly reflected in price. Stochastic at the oversold point and RSI close to touching it. It could give the surprise of giving a significant bounce to the marked lines. The risk is that it has been trading at a loss for some time. "Liminal (Nasdaq: LMNL) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases that have high unmet medical need, including those related to fibrosis in respiratory, liver and kidney diseases."
NASDAQ:LMNLLong
by amateur_trad3r
1
HBIO Bull Case Breaking through the double top barrier, HBIO is now gathering support around the previous resistance level. The stock has been in a steady accumulation stage with a strong uptrend and increasing volume. The strong uptrend should continue. The Benchmark Company has also changed their status from a Speculative Buy to a Buy, as of today. There is enough volume to identify a cup and handle pattern. You can also identify a rising triangle from point X to the support level forming line 1, and point B up to the current low price making up line 2. This is a continuation pattern, indicating the direction of the price movement should continue, which in the current stage is up. All these patterns indicate that HBIO is likely to have a bull run. The price target is $6, a 36% upside from the current price of 4.4
NASDAQ:HBIO
by ayushranjanth